Gen9 raises $25 million in undisclosed venture round

Synthetic biology company Gen9 Inc. (Cambridge, Mass.) raised $25 million from undisclosed investors in an undisclosed venture round. CEO Kevin Munnelly confirmed that the $25 million is in addition to a $21 million series C round raised from tool company Agilent Technologies Inc. (NYSE:A) in April 2013 (see BioCentury Extra, April, 24, 2013). ...